Management ChangeAug 3, 2026, 10:38 AM
Helus Pharma Appoints Michael Halstead as New CEO
AI Summary
Helus Pharma, the commercial operating name of Cybin Inc., announced the immediate appointment of Michael Halstead as its new Chief Executive Officer. Halstead brings 25 years of industry experience, including his role as President of Intra-Cellular Therapies, where he oversaw the company's growth and its $14.6 billion acquisition by Johnson & Johnson. His appointment comes as Helus Pharma advances its lead drug HLP003 through late-stage clinical development, with topline Phase 3 data expected in Q4 2026, and prepares for potential commercialization.
Key Highlights
- Helus Pharma appointed Michael Halstead as Chief Executive Officer, effective immediately.
- Mr. Halstead previously served as President of Intra-Cellular Therapies, Inc.
- He was instrumental in Intra-Cellular's transformation into a commercial biopharmaceutical enterprise and its $14.6 billion sale to Johnson & Johnson in 2025.
- Helus Pharma is preparing for topline data readout for HLP003, its pivotal Phase 3 study for MDD, expected in Q4 2026.
- Enrollment continues for EMBRACE, the second pivotal study for HLP003, and HLP004 is in Phase 2 for GAD.
- The company holds an intellectual property portfolio of over 350 patent applications and 100 granted patents worldwide.
Price Impact
More from HELP